Marinus Pharmaceuticals’ (MRNS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $4.00 target price on the biopharmaceutical company’s stock.

MRNS has been the subject of several other reports. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Royal Bank of Canada dropped their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research report on Monday, September 23rd. Finally, TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 2.2 %

MRNS opened at $0.30 on Thursday. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The business has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.31. The firm has a market cap of $16.66 million, a P/E ratio of -0.12 and a beta of 1.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the second quarter valued at $727,000. Vanguard Group Inc. raised its position in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $813,000. Hussman Strategic Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $206,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.